Carol M. Amato

1.7k citations

34 papers · 1.0k indexed · h-index 16

Cancer Research top 5%
- Cancer Genomics and Diagnostics 4
Oncology top 10%
- Cancer Immunotherapy and Biomarkers 10
- CAR-T cell therapy research 9
- Cutaneous Melanoma Detection and Management 4
Immunology top 10%
- Immunotherapy and Immune Responses 12
- Immune Cell Function and Interaction 5
Molecular Biology
- Melanoma and MAPK Pathways 7
- RNA Interference and Gene Delivery 3
Pathology and Forensic Medicine

Co-authors: William A. Robinson Steven E. Robinson Lynne Bemis Yiqun G. Shellman David G. Coffey Paul F. Erickson Robert Chen Aik Choon Tan
Cited by: Cancer Research Oncology Immunology
Journals: Journal of Clinical Investigation (1 paper)Journal of Clinical Oncology (3 papers)Blood (1 paper)
Partner nations: United States Netherlands Australia

In The Last Decade

Carol M. Amato

33 papers receiving 1.0k citations

Peers

Countries citing papers authored by Carol M. Amato

Since Specialization

Citations

This map shows the geographic impact of Carol M. Amato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol M. Amato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol M. Amato more than expected).

Fields of papers citing papers by Carol M. Amato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol M. Amato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol M. Amato. The network helps show where Carol M. Amato may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Carol M. Amato, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Carol M. Amato Line = papers co-authored together Carol M. Amato links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors Journal of Clinical Investigation ·Anders Lade Nielsen,Gabriella Albert,Amelia Sánchez,Jiangli Chen,Jing Liu,Araceli Dávalos,Degui Geng,Xander Bradeen,Jennifer D. Hintzsche,William A. Robinson,Martin D. McCarter,Carol M. Amato,Richard P. Tobin,Kasey L. Couts,Breelyn A. Wilky,Eduardo Davila	2024	4
2	A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance Clinical Cancer Research ·Ankita Mitra,Brian Thompson,Ann Strange,Carol M. Amato,Melinda Vassallo,Igor Dolgalev,Jonathan Hester-McCullough,Tomoaki Muramatsu,Diana Kimono,Amrutesh S. Puranik,Jeffrey S. Weber,David Woods	2023	9
3	CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy The Journal of Immunology ·Brian Thompson,Ann Strange,Carol M. Amato,Jonathan Hester-McCullough,Amod A. Sarnaik,Jeffrey S. Weber,David Woods	2023	2
4	Circulating CD8 ⁺ mucosal‐associated invariant T cells correlate with improved treatment responses and overall survival in anti‐PD‐1‐treated melanoma patients Clinical & Translational Immunology ·Victoria M. Vorwald,Dana M. Davis,Robert J. Van Gulick,Robert J. Torphy,Jessica S.W. Borgers,Jared Klarquist,Kasey L. Couts,Carol M. Amato,Dasha T. Cogswell,Mayumi Fujita,Moriah J. Castleman,Timothy Davis,Catherine Lozupone,Theresa Medina,William A. Robinson,Laurent Gapin,Martin D. McCarter,Richard P. Tobin	2022	15
5	Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma Molecular Cancer Therapeutics ·Kelsey W. Nassar,Jennifer D. Hintzsche,Stacey M. Bagby,Veronica L. Espinoza,Christophe Langouët-Astrié,Carol M. Amato,Tugs‐Saikhan Chimed,Mayumi Fujita,William A. Robinson,Aik Choon Tan,Rebecca E. Schweppe	2021	24
6	Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics Journal of Investigative Dermatology ·Nabanita Mukherjee,Chiara R. Dart,Carol M. Amato,Adam Honig-Frand,James R. Lambert,Karoline A. Lambert,William A. Robinson,Richard P. Tobin,Martin D. McCarter,Kasey L. Couts,Mayumi Fujita,David A. Norris,Yiqun G. Shellman	2021	4
7	Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma Cancers ·Nabanita Mukherjee,Carol M. Amato,Jenette Skees,Kaleb J. Todd,Karoline A. Lambert,William A. Robinson,Robert J. Van Gulick,Ryan Weight,Chiara R. Dart,Richard P. Tobin,Martin D. McCarter,Mayumi Fujita,David A. Norris,Yiqun G. Shellman	2020	26
8	Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas Melanoma Research ·Blair Holman,Robert J. Van Gulick,Carol M. Amato,Morgan MacBeth,Kurtis D. Davies,Dara L. Aisner,William A. Robinson,Kasey L. Couts	2020	24
9	IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients Frontiers in Oncology ·Richard P. Tobin,Kimberly R. Jordan,Puja Kapoor,Eric Spongberg,Dana M. Davis,Victoria M. Vorwald,Kasey L. Couts,Dexiang Gao,Derek Smith,Jessica S.W. Borgers,Steven E. Robinson,Carol M. Amato,René González,Karl D. Lewis,William A. Robinson,Virginia F. Borges,Martin D. McCarter	2019	99
10	Biomarkers to predict immune-related adverse events with checkpoint inhibitors. Journal of Clinical Oncology ·Lia Head,Nicholas T. Gorden,Robert J. Van Gulick,Carol M. Amato,Ashley Frazer‐Abel,William A. Robinson,V. Michael Holers,Wells A. Messersmith,S. Lindsey Davis	2019	14
11	Abstract 5002: Investigating the role of NF- κB signaling and immune checkpoint blockade therapy in melanoma Cancer Research ·Keith Wells,Jennifer D. Hintzsche,Carol M. Amato,Richard P. Tobin,Victoria M. Vorwald,Martin D. McCarter,Yiqun G. Shellman,Aik Choon Tan,William A. Robinson	2019	2
12	BH3 mimetics induce apoptosis independent of DRP-1 in melanoma Cell Death and Disease ·Nabanita Mukherjee,Andrew Strosnider,Bay Vagher,Karoline A. Lambert,Sarah Slaven,William A. Robinson,Carol M. Amato,Kasey L. Couts,Judson Bemis,Jacqueline A. Turner,David A. Norris,Yiqun G. Shellman	2018	23
13	IMPACT web portal: oncology database integrating molecular profiles with actionable therapeutics BMC Medical Genomics ·Jennifer D. Hintzsche,Minjae Yoo,Jihye Kim,Carol M. Amato,William A. Robinson,Aik Choon Tan	2018	4
14	Identification of somatic mutations and neoantigens to predict development of autoimmune adverse events to immune therapy in melanoma. Journal of Clinical Oncology ·Keith Wells,Carol M. Amato,Jennifer D. Hintzsche,William A. Robinson	2017	4
15	Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma Melanoma Research ·Jennifer D. Hintzsche,Nicholas T. Gorden,Carol M. Amato,Jihye Kim,Kelsey E. Wuensch,Steven E. Robinson,Allison J. Applegate,Kasey L. Couts,Theresa Medina,Keith Wells,J. Wisell,Martin D. McCarter,Neil F. Box,Yiqun G. Shellman,René González,Karl D. Lewis,John J. Tentler,Aik Choon Tan,William A. Robinson	2017	101
16	Long Term Storage of Dry versus Frozen RNA for Next Generation Molecular Studies PLoS ONE ·Eric Seelenfreund,William A. Robinson,Carol M. Amato,Aik Choon Tan,Jihye Kim,Steven E. Robinson	2014	40
17	Therapeutic monoclonal antibodies in human breast milk Melanoma Research ·Elle Ross,Steven E. Robinson,Carol M. Amato,Colette McMillan,Jay Y. Westcott,Tiffany M. Wolf,William A. Robinson	2014	10
18	Recovery of MicroRNA from Stored Human Peripheral Blood Samples Biopreservation and Biobanking ·Eric Seelenfreund,Steven E. Robinson,Carol M. Amato,Lynne Bemis,William A. Robinson	2011	5
19	The RET G691S polymorphism is a germline variant in desmoplastic malignant melanoma Melanoma Research ·Jodie Barr,Carol M. Amato,Steven E. Robinson,Nicole Kounalakis,William A. Robinson	2011	9
20	Gastrointestinal Melanoma or Clear Cell Sarcoma? Molecular Evaluation of 7 Cases Previously Diagnosed as Malignant Melanoma The American Journal of Surgical Pathology ·Pamela L. Lyle,Carol M. Amato,James E. Fitzpatrick,William A. Robinson	2008	52

About Carol M. Amato

Carol M. Amato is a scholar working on Immunology, Oncology and Cancer Research, having authored 34 papers that have together received 1.0k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (12 papers), Cancer Immunotherapy and Biomarkers (10 papers), CAR-T cell therapy research (9 papers), Melanoma and MAPK Pathways (7 papers), Immune Cell Function and Interaction (5 papers), Cancer Genomics and Diagnostics (4 papers), Cutaneous Melanoma Detection and Management (4 papers) and RNA Interference and Gene Delivery (3 papers). The work is most often cited by research in Cancer Research (327 citations), Oncology (368 citations) and Immunology (268 citations). Carol M. Amato has collaborated with scholars based in United States, Netherlands and Australia. Frequent co-authors include William A. Robinson, Steven E. Robinson, Lynne Bemis, Yiqun G. Shellman, David G. Coffey, Paul F. Erickson, Robert Chen, Aik Choon Tan, Kasey L. Couts and S. Gail Eckhardt. Their work appears in journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact